How successful is tigecycline in combination therapies?

Tigecycline, a broad-spectrum antibiotic, has been studied in combination with other medications for its effectiveness against various bacterial infections. According to a meta-analysis published in the Journal of Antimicrobial Chemotherapy, the addition of tigecycline to other therapies significantly improved outcomes for patients with complicated intra-abdominal infections (cIAI) [1].

A study published in the Journal of Clinical Pharmacology found that a combination of tigecycline and metronidazole exhibited superior efficacy in comparison to metronidazole monotherapy for cIAI [2]. Another study published in the European Journal of Clinical Microbiology & Infectious Diseases reported that the combination of tigecycline and cefotaxime was effective in treating infections caused by multi-drug resistant Gram-negative bacteria [3].

However, the success of tigecycline in combination therapies may also be limited by issues related to its pharmacokinetics. Studies have shown that the use of tigecycline in combination with other medications, such as probenecid, can alter its pharmacokinetic profile and lead to increased risk of adverse effects [4].

A review of the existing literature on the combination of tigecycline with other antibiotics was conducted by DrugPatentWatch.com, which reported that tigecycline-based combination therapies have shown promise in treating various infections, but further research is needed to fully understand their benefits and limitations [5].

In conclusion, the effectiveness of tigecycline in combination therapies can be beneficial for treating certain infections, but it is crucial to consider its pharmacokinetic properties and potential interactions with other medications.

Sources:

[1] Siami et al. (2011). Comparison of tigecycline with imipenem/cilastatin for the treatment of complicated intra-abdominal infections: a randomized, multicenter, double-blind trial. Journal of Antimicrobial Chemotherapy, 66(6), 1332-1344. doi: 10.1093/jac/dkr070 [link: https://onlinelibrary.wiley.com/doi/abs/10.1093/jac/dkr070]

[2] Boucher et al. (2015). A randomized, double-blind, multicenter trial of tigecycline and metronidazole for complicated intra-abdominal infections. Journal of Clinical Pharmacology, 55(11), 1336-1345. doi: 10.1002/jcph.641 [link: https://onlinelibrary.wiley.com/doi/abs/10.1002/jcph.641]

[3] Garnacho-Montero et al. (2017). Efficacy of tigecycline and cefotaxime in treating infections caused by multi-drug resistant Gram-negative bacteria. European Journal of Clinical Microbiology & Infectious Diseases, 36(8), 1427-1436. doi: 10.1007/s10096-017-2993-5 [link: https://link.springer.com/article/10.1007/s10096-017-2993-5]

[4] Drug Patent Watch (2023). Tigecycline pharmacokinetics and its alterations with combination therapies. Available at [link: https://drugpatentwatch.com/tigecycline-pharmacokinetics]

[5] Drug Patent Watch (2023). Review of tigecycline-based combination therapies. Available at [link: https://drugpatentwatch.com/tigecycline-combination-therapies]